If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
'We know it works' but it's been locked in a warehouse since Nov 2011.
Not sure if the article is visible to all (?) but the summary at end states that "“We’re not going to be ready,” Katrine Wallace, epidemiologist at the University of Illinois, said. “We’re not even dealing with what’s right in front of us.”
Posting IN THE CONTEXT of current H5N1 threat in the US. We know that "Pre-clinical research conducted by Synairgen of IFN-β (at concentrations readily achievable following inhaled delivery of SNG001) shows the inhibition of a broad range of viruses in cell-based assays including: viruses which cause seasonal cold (e.g., RSV, Rhinovirus) and flu infections highly pathogenic viruses such as H5N1 ‘bird flu’ and Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)".
MrCosts2much.
Anyone who can afford to spank £500k on a speculative stock can afford to attend an AGM. But yeah, I’ll help fund MrCosts trip and buy the first round.
O/T
seen on another BB clutching at straws I know , this and long Covid are opportunities which you would think Synairgen team would be exploiting
https://www.gov.uk/government/news/new-five-year-plan-to-combat-antimicrobial-resistance
https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market
Do we need to set up a GoFundMe for Mr Cost's trip to the AGM?
Going to the AGM: useless.
Unless for the drinks afterwards
Then again, he may be travelling in from his trading desk at Citadel, 120 London Wall London. ..
Fantasy Heights, 1 Joke Street, Liarsville H0H0 XXX.
Did I miss anything?
£500? Where are you travelling in from?
I'm sure some of us on here will chip in to over your costs. I'm willing to!
End of June*
'Tell them at the AGM' - yawn.
They have my mobile number and email address. I can't do anymore. I'm not wasting the best of £500 to attend an AGM to be told 'communications will improve' and 'we are suffering too on £350k salaries'
Trials to start end of month?
"You have been saying for years you will go but miraculously things happen which mean you can’t make it, will you be going this year?"
This!!! ^^^
MrCosts you could go to the AGM and tell them!
You have been saying for years you will go but miraculously things happen which mean you can’t make it, will you be going this year?
You're the joke.
There you go.
Post P3 failure - target price 220p
Updated target price 8p with trials to start next month!
The whole saga is a joke.
The last Paul Cuddon Broker Note information I have is dd 17 March 2022 and it was on the Activ-2 update but prior Sprinter results:
"Current share price: 26p
Target price: 220p"
NUMIS / Paul Cuddon – 17 March 2022
Was there a later report published after Sprinter?
DB will not have published a forecast this isn't current. Any previous forecast and rating will have been checked for accuracy against all current available information (peer,market sector - etc) before being published. I don't believe there is any previous note published by Paul Cuddon that pegged a forecast of 8p, unless I missed it? So I think this has to be new, and based on current info.
DocDan - Numis specialise in UK smaller companies and research. DB very little, so I’m guessing that’s why they wanted them. I’m certain Paul Cuddon hasn’t changed his mind on Synairgen and he’s just said “hold” and quoted the SP when he lodged it. In other words, “nothing to see here”. But I could be wrong. We could do with getting hold of his note… I assume there will be an updated one, even if it’s just with DB’s logo at the top.
I have some of his old notes with contact details on, but I’m guessing they’ll now be obsolete.
Fruits - let's be honest here, we've not had any positive news for over nearly 2.5 years.
The drug hasn't been trialled on a patient since Nov 2021.
The company won't update us or even talk to us.
Trials to start next month? Really?
I would love to find something positive.
Attending conferences is something this company has done for the last 20 years.
Posting a link about something in America that might happen later this year isn't news either.
Absolutely nothing to get excited about.
Oddly, I have taken some encouragement from reading some recent comments here. Why have DB issued this assessment after 7 months?
Presumably, the analyst has worked for DB since the Numis acquisition? It would seem reasonable for him to have reissued an updated Synairgen broker’s note before now?
Has the analyst been prompted recently by the company, or by TFG perhaps, to begin following Synairgen again and to issue an initial assessment to lay down a marker?
This supposes that there are going to be developments ahead, and with them an increase in share price. It has happened with Synairgen before. In early January 2020, the share price was around the current level. Successive developments brought with them significant share price increases culminating in the post P2 moonshot, when the share price rose by 3OX the January 2020 value.
Given a successful outcome to the strategy from September 2023, we could well see success of this kind being repeated? Having brokers on board to monitor the progress and issue advice to investors is an essential part of this process.
I remain somewhat sceptical until we receive news from Synairgen on their strategy's progress. However, today’s note could well be the start of something provided it is followed by positive news on the P2 trials? Until that happens, there is little to discuss. I am guardedly optimistic, and shall continue to check each morning for that elusive RNS.
All IMHO. GLALTIs.
I don’t think I’ve ever come across an investor who is equally dismayed by the thought of an update or a positive broker rating. You seem happiest at the thought of the company failing. Such a strange behaviour.
DocDan, the “number” is not an arbitrary one. It is based on is level of analysis of information currently available to the the Analyst.
Not sure what's worse an update from Marsden or a brokers note
I've no idea how this all works but if DB took over Numis presumably they HAVE to issue a new broker's note at some point reasonably close to the acquisition. Is this how it works. And in that context is this not - 7 months on - routine and as unremarkable as the number quoted.
If this is entirely wrong please offer a correction.